Gene Logic Expands Contract Study Services Capacity by More Than 50 Percent to Meet Growing Pharmaceutical Industry Need; With A

Gene Logic Inc. (NASDAQ:GLGC) announced today it has
completed expansion and upgrade of its contract study services
facilities, increasing its general toxicology testing capacity by 55
percent to meet growing demand from pharmaceutical and biotechnology
clients for nonclinical testing. Gene Logic Laboratories Inc., the
Company's contract study services business unit, now has approximately
100,000 square feet of facilities dedicated to nonclinical testing
services. Additionally, Gene Logic added skilled staff and enhanced
training programs for new and existing staff.
   V.W. Brinkerhoff III, senior vice president and general manager,
Gene Logic Laboratories, commented, "Drug candidate toxicology testing
is essential to the drug development and approval process, and the
demand for testing has grown faster than the industry's ability to
provide it. With this expansion of facilities and staff, we have
positioned Gene Logic as a prime partner for our current and potential
client base. The added space and specialized facilities enable Gene
Logic to better address increasing client requirements with accuracy
and speed."

   Gene Logic Overview

   Gene Logic aspires to be the most valued drug development
solutions partner for the pharmaceutical industry. Gene Logic applies
its broad and unique mix of technologies, talent and methodologies to
work on behalf of its partners to enable pharmaceutical and
biotechnology companies to make more informed, more reliable and more
predictive decisions at each point in the highly complex and costly
drug development process. For more information, visit
www.genelogic.com or call toll-free - 1/800/GENELOGIC.